The FDA asked Novo Nordisk and Eli Lilly to remove warnings about suicidal ideation or behavior from the labels of their blockbuster GLP-1 weight loss drugs.
Novo’s Saxenda and Wegovy, as well as Lilly’s Zepbound …
Read More from Endpoints News
FDA asks Lilly, Novo to remove suicide warnings from GLP-1 labels
